Key result
Serum Glycogen Synthase 3 Beta levels show promise as a biomarker to refine HF care.
Why the study?
Careful use of biomarkers might help to refine diagnosis and management and improve prognosis of heart failure patients.
Serum Glycogen Synthase 3 Beta is discussed as a potential biomarker to refine the diagnosis and management of heart failure.
Answers are grounded in this paper and cite their sources.
Does not support clinical use of serum GSK3β in HF; leaves open its biomarker potential pending validation studies.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Alesso et al. (2024) conducted a review in Heart failure. Serum Glycogen Synthase 3 Beta Levels was evaluated. Serum Glycogen Synthase 3 Beta levels are proposed as a promissory biomarker to refine the diagnosis, management, and prognosis of patients with heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: